EVENITY (2 SYRINGES) (romosozumab-aqqg)
OSTEOPOROSIS AGENTS·OSTEOPOROSIS IN POSTMENOPAUSAL WOMAN AT HIGH RISK FOR FRACTURE
AMGEN
Indication
Osteoporosis in postmenopausal woman at high risk for fracture
Osteoporosis in a postmenopausal woman at high risk for fracture refers to a systemic skeletal disorder characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of bone tissue following natural or surgical menopause. Read more about Osteoporosis in postmenopausal woman at high risk for fracture
36 drugs 29 manufacturers
Drugs that treat it
Common Osteoporosis in postmenopausal woman at high risk for fracture therapies.
TERIPARATIDE
OSTEOPOROSIS AGENTS·GLUCOCORTICOID-INDUCED OSTEOPOROSIS·+2
APOTEX CORP
RECLAST (zoledronic acid in mannitol and water for injection)
HYPERCALCEMIA AGENTS·PAGET'S DISEASE OF BONE·+5
SANDOZ INC.
TERIPARATIDE
OSTEOPOROSIS AGENTS·GLUCOCORTICOID-INDUCED OSTEOPOROSIS·+2
PRASCO LABS
ZOLEDRONIC ACID (zoledronic acid in mannitol and water for injection)
HYPERCALCEMIA AGENTS·PAGET'S DISEASE OF BONE·+5
MEITHEAL PHARMA
ZOLEDRONIC ACID (zoledronic acid in mannitol and water for injection)
HYPERCALCEMIA AGENTS·PAGET'S DISEASE OF BONE·+5
FOSUN PHARMA US
TERIPARATIDE
OSTEOPOROSIS AGENTS·GLUCOCORTICOID-INDUCED OSTEOPOROSIS·+2
TEVA USA
JUBBONTI (denosumab-bbdz)
HYPERCALCEMIA AGENTS·GLUCOCORTICOID-INDUCED OSTEOPOROSIS·+4
SANDOZ
BONSITY (teriparatide)
OSTEOPOROSIS AGENTS·GLUCOCORTICOID-INDUCED OSTEOPOROSIS·+2
ALVOGEN INC
Filter & compare in the drug finder →Opens the drug finder with Osteoporosis in postmenopausal woman at high risk for fracture preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonOsteoporosis in a postmenopausal woman at high risk for fracture refers to a systemic skeletal disorder characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of bone tissue following natural or surgical menopause.
Pathophysiologically, the cessation of ovarian function leads to estrogen deficiency, accelerating osteoclast-mediated bone resorption beyond bone formation and resulting in progressive skeletal fragility.
The high-risk designation identifies patients with an elevated probability of imminent or future fragility fractures, clinically defined by criteria such as a history of osteoporotic or fragility fractures, very low bone mineral density (T-score of –2.5 or lower), multiple clinical fracture risk factors, a high FRAX score, or previous failure or intolerance to other osteoporosis therapies.
- fda.gov
Osteoporosis in a postmenopausal woman at high risk for fracture refers to a systemic skeletal disorder characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of bone tissue following natural or surgical menopause
- osteoporosis.foundation
Osteoporosis in a postmenopausal woman at high risk for fracture refers to a systemic skeletal disorder characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of bone tissue following natural or surgical menopause
- fda.gov
Pathophysiologically, the cessation of ovarian function leads to estrogen deficiency, accelerating osteoclast-mediated bone resorption beyond bone formation and resulting in progressive skeletal fragility
- menopause.org
Pathophysiologically, the cessation of ovarian function leads to estrogen deficiency, accelerating osteoclast-mediated bone resorption beyond bone formation and resulting in progressive skeletal fragility
- obgproject.com
The high-risk designation identifies patients with an elevated probability of imminent or future fragility fractures, clinically defined by criteria such as a history of osteoporotic or fragility fractures, very low bone mineral density (T-score of –2.5 or lower), multiple clinical fracture risk factors, a high FRAX score, or previous failure or intolerance to other osteoporosis therapies
- ajmc.com
The high-risk designation identifies patients with an elevated probability of imminent or future fragility fractures, clinically defined by criteria such as a history of osteoporotic or fragility fractures, very low bone mineral density (T-score of –2.5 or lower), multiple clinical fracture risk factors, a high FRAX score, or previous failure or intolerance to other osteoporosis therapies
- consultant360.com
The high-risk designation identifies patients with an elevated probability of imminent or future fragility fractures, clinically defined by criteria such as a history of osteoporotic or fragility fractures, very low bone mineral density (T-score of –2.5 or lower), multiple clinical fracture risk factors, a high FRAX score, or previous failure or intolerance to other osteoporosis therapies
Personalize your experience
Follow Osteoporosis in postmenopausal woman at high risk for fracture and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.